PortalPublikationenAdverse event management in patients with relapsed and refra...

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

Standard

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. / Moreau, Philippe; Dimopoulos, Meletios A; Richardson, Paul G; Siegel, David S; Cavo, Michele; Corradini, Paolo; Weisel, Katja; Delforge, Michel; O'Gorman, Peter; Song, Kevin; Chen, Christine; Bahlis, Nizar; Oriol, Albert; Hansson, Markus; Kaiser, Martin; Anttila, Pekka; Raymakers, Reinier; Joao, Cristina; Cook, Gordon; Sternas, Lars; Biyukov, Tsvetan; Slaughter, Ana; Hong, Kevin; Herring, Jennifer; Yu, Xin; Zaki, Mohamed; San-Miguel, Jesus.

in: EUR J HAEMATOL, Jahrgang 99, Nr. 3, 09.2017, S. 199-206.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Moreau, P, Dimopoulos, MA, Richardson, PG, Siegel, DS, Cavo, M, Corradini, P, Weisel, K, Delforge, M, O'Gorman, P, Song, K, Chen, C, Bahlis, N, Oriol, A, Hansson, M, Kaiser, M, Anttila, P, Raymakers, R, Joao, C, Cook, G, Sternas, L, Biyukov, T, Slaughter, A, Hong, K, Herring, J, Yu, X, Zaki, M & San-Miguel, J 2017, 'Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis', EUR J HAEMATOL, Jg. 99, Nr. 3, S. 199-206. https://doi.org/10.1111/ejh.12903

APA

Moreau, P., Dimopoulos, M. A., Richardson, P. G., Siegel, D. S., Cavo, M., Corradini, P., Weisel, K., Delforge, M., O'Gorman, P., Song, K., Chen, C., Bahlis, N., Oriol, A., Hansson, M., Kaiser, M., Anttila, P., Raymakers, R., Joao, C., Cook, G., ... San-Miguel, J. (2017). Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. EUR J HAEMATOL, 99(3), 199-206. https://doi.org/10.1111/ejh.12903

Vancouver

Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P et al. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. EUR J HAEMATOL. 2017 Sep;99(3):199-206. https://doi.org/10.1111/ejh.12903

Bibtex

@article{b3b0cec0187042a0ae48ed7c7c137f45,
title = "Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis",
abstract = "OBJECTIVES: Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management.METHODS: This analysis included 1088 patients who received ≥ 2 prior therapies, including lenalidomide and bortezomib, and progressed ≤ 60 days of last therapy. Patients received 28-day cycles of pomalidomide 4 mg/day on days 1-21 and low-dose dexamethasone 40 mg (20 mg if aged > 75 years) weekly until disease progression or unacceptable toxicity. Thromboprophylaxis was required.RESULTS: The most common grade 3/4 AEs were neutropenia (56.2%), anemia (32.3%), and thrombocytopenia (25.8%), which occurred within the first few cycles of treatment. Grade 3/4 infections occurred in 33.7% patients, of whom 13.9% had pneumonia, and 40.3% had neutropenia. Pomalidomide dose reductions or interruptions were reported in 24.2% and 66.0% of patients, respectively. AEs were managed by dose modifications and/or supportive care.CONCLUSIONS: Pomalidomide plus low-dose dexamethasone showed an acceptable safety profile, and AEs were well managed according to study protocols and established guidelines.",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Combined Modality Therapy, Dexamethasone, Disease Management, Drug Resistance, Neoplasm, Drug-Related Side Effects and Adverse Reactions, Humans, Middle Aged, Multicenter Studies as Topic, Multiple Myeloma, Neoplasm Recurrence, Local, Thalidomide, Time Factors, Journal Article",
author = "Philippe Moreau and Dimopoulos, {Meletios A} and Richardson, {Paul G} and Siegel, {David S} and Michele Cavo and Paolo Corradini and Katja Weisel and Michel Delforge and Peter O'Gorman and Kevin Song and Christine Chen and Nizar Bahlis and Albert Oriol and Markus Hansson and Martin Kaiser and Pekka Anttila and Reinier Raymakers and Cristina Joao and Gordon Cook and Lars Sternas and Tsvetan Biyukov and Ana Slaughter and Kevin Hong and Jennifer Herring and Xin Yu and Mohamed Zaki and Jesus San-Miguel",
note = "{\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2017",
month = sep,
doi = "10.1111/ejh.12903",
language = "English",
volume = "99",
pages = "199--206",
journal = "EUR J HAEMATOL",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

AU - Moreau, Philippe

AU - Dimopoulos, Meletios A

AU - Richardson, Paul G

AU - Siegel, David S

AU - Cavo, Michele

AU - Corradini, Paolo

AU - Weisel, Katja

AU - Delforge, Michel

AU - O'Gorman, Peter

AU - Song, Kevin

AU - Chen, Christine

AU - Bahlis, Nizar

AU - Oriol, Albert

AU - Hansson, Markus

AU - Kaiser, Martin

AU - Anttila, Pekka

AU - Raymakers, Reinier

AU - Joao, Cristina

AU - Cook, Gordon

AU - Sternas, Lars

AU - Biyukov, Tsvetan

AU - Slaughter, Ana

AU - Hong, Kevin

AU - Herring, Jennifer

AU - Yu, Xin

AU - Zaki, Mohamed

AU - San-Miguel, Jesus

N1 - © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2017/9

Y1 - 2017/9

N2 - OBJECTIVES: Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management.METHODS: This analysis included 1088 patients who received ≥ 2 prior therapies, including lenalidomide and bortezomib, and progressed ≤ 60 days of last therapy. Patients received 28-day cycles of pomalidomide 4 mg/day on days 1-21 and low-dose dexamethasone 40 mg (20 mg if aged > 75 years) weekly until disease progression or unacceptable toxicity. Thromboprophylaxis was required.RESULTS: The most common grade 3/4 AEs were neutropenia (56.2%), anemia (32.3%), and thrombocytopenia (25.8%), which occurred within the first few cycles of treatment. Grade 3/4 infections occurred in 33.7% patients, of whom 13.9% had pneumonia, and 40.3% had neutropenia. Pomalidomide dose reductions or interruptions were reported in 24.2% and 66.0% of patients, respectively. AEs were managed by dose modifications and/or supportive care.CONCLUSIONS: Pomalidomide plus low-dose dexamethasone showed an acceptable safety profile, and AEs were well managed according to study protocols and established guidelines.

AB - OBJECTIVES: Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management.METHODS: This analysis included 1088 patients who received ≥ 2 prior therapies, including lenalidomide and bortezomib, and progressed ≤ 60 days of last therapy. Patients received 28-day cycles of pomalidomide 4 mg/day on days 1-21 and low-dose dexamethasone 40 mg (20 mg if aged > 75 years) weekly until disease progression or unacceptable toxicity. Thromboprophylaxis was required.RESULTS: The most common grade 3/4 AEs were neutropenia (56.2%), anemia (32.3%), and thrombocytopenia (25.8%), which occurred within the first few cycles of treatment. Grade 3/4 infections occurred in 33.7% patients, of whom 13.9% had pneumonia, and 40.3% had neutropenia. Pomalidomide dose reductions or interruptions were reported in 24.2% and 66.0% of patients, respectively. AEs were managed by dose modifications and/or supportive care.CONCLUSIONS: Pomalidomide plus low-dose dexamethasone showed an acceptable safety profile, and AEs were well managed according to study protocols and established guidelines.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Clinical Trials as Topic

KW - Combined Modality Therapy

KW - Dexamethasone

KW - Disease Management

KW - Drug Resistance, Neoplasm

KW - Drug-Related Side Effects and Adverse Reactions

KW - Humans

KW - Middle Aged

KW - Multicenter Studies as Topic

KW - Multiple Myeloma

KW - Neoplasm Recurrence, Local

KW - Thalidomide

KW - Time Factors

KW - Journal Article

U2 - 10.1111/ejh.12903

DO - 10.1111/ejh.12903

M3 - SCORING: Journal article

C2 - 28504846

VL - 99

SP - 199

EP - 206

JO - EUR J HAEMATOL

JF - EUR J HAEMATOL

SN - 0902-4441

IS - 3

ER -